Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
The processing of proglucagon in intestinal L cells results in the formation of glucagon, GLP-1, and GLP-2. The GLP-1 molecule becomes active through the effect of proconvertase 1, and it is inactivated by dipeptidyl peptidase IV (DPP-IV), so that the half-life of endogenous GLP-1 is 2-3 min. GLP-1 stimulates insulin secretion from β cells in the islets of Langerhans. Human studies show that infusion of GLP-1 results in slowing of gastric emptying and increased fasting and postprandial gastric volumes. Retardation of gastric emptying reduces postprandial glycemia. Exendin-4 is a peptide agonist of the GLP-1 receptor that promotes insulin secretion. Chemical modifications of exendin-4 and GLP-1 molecules have been accomplished to prolong the half-life of GLP-1 agonists or analogs. This chapter reviews the effects of GLP-1-related drugs used in treatment of diabetes or obesity on gastric motor functions, chiefly gastric emptying. The literature shows that diverse methods have been used to measure effects of the GLP-1-related drugs on gastric emptying, with most studies using the acetaminophen absorption test which essentially measures gastric emptying of liquids during the first hour and capacity to absorb the drug over 4-6 h, expressed as AUC. The most valid measurements by scintigraphy (solids or liquids) and acetaminophen absorption at 30 or 60 min show that GLP-1-related drugs used in diabetes or obesity retard gastric emptying, and this is associated with reduced glycemia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Amylin analogs and GLP-1 receptor agonists, particularly short-acting agents, can worsen gastric emptying and should be considered when symptoms arise or deteriorate (Maselli et al., 2021; Vella et al., 2002).”
From Autonomic nervous system and gastrointestinal manifestations with an emphasis on gastric dysfunction (2026) · cites this paper as Maselli et al., 2021
In the citing paper
“Structural modifications of the GLP-1 molecule led to the development of GLP-1RAs with prolonged half-life, enabling sustained glycemic control and weight reduction [33,38,40]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [38]
In the citing paper
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70-85% of patients and lead to treatment discontinuation [22,38,41,60,61]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [38]
In the citing paper
“In the GI tract, GLP-1 acts on myoenteric neurons and inhibits vagal activity, thereby delaying gastric emptying and lowering gastric acid secretion, which further promotes satiety and reduces caloric intake [38,39]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [38]
In the citing paper
“GLP‐1 receptor agonists are novel drugs used to treat diabetes mellitus and obesity, and their beneficial effects are mediated, at least in part, by retardation of gastric emptying [ 33 , 34 ].”
From European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management (2025) · cites this paper as [34]
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Cholecystokinin decreases food intake in rats.
Gibbs, J., Young, R. C., & Smith, G. P. (1973) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0034870 · Cited by 1,491
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Gastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Gutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Zinman, B., Hoogwerf, B. J., Durán García, S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 427
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Read, N. W., McFarlane, A., Kinsman, R. I., Bates, T. E., Blackhall, N. W., Farrar, G. B. J., Hall, J. C., Moss, G., Morris, A. P., O'Neill, B., et al. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90411-6 · Cited by 329
Alvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., García‐Cuartero, B., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., De Cáceres, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 305
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H. J., & Göke, B. (2006) · Gut · doi:10.1136/gut.2004.059741 · Cited by 277
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245
Deane, A. M., Nguyen, N. Q., Stevens, J. E., Fraser, R. J. L., Holloway, R. H., Besanko, L. K., Burgstad, C., Jones, K. L., Chapman, M. J., Rayner, C. K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1503 · Cited by 238
Delgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235
Self-citationHayes, M. R., Bradley, L., & Grill, H. J. (2009) · Endocrinology · doi:10.1210/en.2008-1479 · Cited by 228
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
Halawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224
Self-citationLittle, T. J., Pilichiewicz, A. N., Russo, A., Phillips, L., Jones, K. L., Nauck, M. A., Wishart, J., Horowitz, M., & Feinle-Bisset, C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2220 · Cited by 212
Ritzel, R., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 210
Szarka, L. A., Camilleri, M., Vella, A., Burton, D., Baxter, K., Simonson, J., & Zinsmeister, A. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.01.009 · Cited by 209
Self-citationRoles of the Gut in Glucose Homeostasis
Holst, J. J., Gribble, F., Horowitz, M., & Rayner, C. K. (2016) · Diabetes Care · doi:10.2337/dc16-0351 · Cited by 205
Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons
Vrang, N., Phifer, C. B., Corkern, M. M., & Berthoud, H.-R. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00732.2002 · Cited by 204
Vella, A., Bock, G., Giesler, P. D., Burton, D. B., Serra, D. B., Saylan, M. L., Dunning, B. E., Foley, J. E., Rizza, R. A., & Camilleri, M. (2007) · Diabetes · doi:10.2337/db07-0136 · Cited by 201
Self-citationAcosta, A., Camilleri, M., Shin, A., Vazquez-Roque, M. I., Iturrino, J., Burton, D., O’Neill, J., Eckert, D., & Zinsmeister, A. R. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.020 · Cited by 200
Self-citationWettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.5.g984 · Cited by 197
Garber, A., Henry, R. R., Ratner, R., Hale, P., Chang, C. T., & Bode, B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01356.x · Cited by 196
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Umapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193
Incretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 188
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
The physiological role of GLP-1 in human: incretin, ileal brake or more?
Schirra, J. R. J., & Göke, B. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.018 · Cited by 166
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C., Musi, N., DeFronzo, R. A., & Cersosimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 157
Carr, R. D., Larsen, M. O., Jelic, K., Lindgren, O., Vikman, J., Holst, J. J., Deacon, C. F., & Ahrén, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2054 · Cited by 154
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 153
Fineman, M., Mace, K., Diamant, M., Darsow, T., Cirincione, B., Porter, T. K. B., Kinninger, L. A., & Trautmann, M. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01561.x · Cited by 151
Lorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Adam, T. C. M., & Westerterp-Plantenga, M. S. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041335 · Cited by 136
Schirra, J., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2002) · Gut · doi:10.1136/gut.50.3.341 · Cited by 130
Methods for measurement of gastric motility
Szarka, L. A., & Camilleri, M. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90467.2008 · Cited by 130
Self-citationNakatani, Y., Maeda, M., Matsumura, M., Shimizu, R., Banba, N., Aso, Y., Yasu, T., & Harasawa, H. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.009 · Cited by 126
Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
Nutrient detection by incretin hormone secreting cells
Diakogiannaki, E., Gribble, F. M., & Reimann, F. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.12.001 · Cited by 123
Barrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., & Hardy, T. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01364.x · Cited by 120
Deane, A. M., Chapman, M. J., Fraser, R. J. L., Summers, M. J., Zaknic, A. V., Storey, J. P., Jones, K. L., Rayner, C. K., & Horowitz, M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d9d87a · Cited by 104
Halim, M. A., Degerblad, M., Sundbom, M., Karlbom, U., Holst, J. J., Webb, D.-L., & Hellström, P. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02006 · Cited by 102
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
GLP‐1 regulates gastroduodenal motility involving cholinergic pathways
Schirra, J. R. J., Nicolaus, M., Woerle, H. J., Struckmeier, C. A., Katschinski, M., & Göke, B. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01246.x · Cited by 86
Jones, K. L., Huynh, L. Q., Hatzinikolas, S., Rigda, R. S., Phillips, L. K., Pham, H. T., Marathe, C. S., Wu, T., Malbert, C., Stevens, J. E., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13956 · Cited by 83
Delgado-Aros, S., Vella, A. V., Camilleri, M., Low, P. A., Burton, D. D., Thomforde, G. M., & Stephens, D. A. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00422.x · Cited by 82
Self-citationVilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 81
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
Acosta, A., Camilleri, M., Burton, D., O'Neill, J., Eckert, D., Carlson, P., & Zinsmeister, A. R. (2015) · Physiological Reports · doi:10.14814/phy2.12610 · Cited by 78
Self-citationIntestinal GLP-1 and satiation: from man to rodents and back
Steinert, R. E., Beglinger, C., & Langhans, W. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.172 · Cited by 78
Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin
Kothare, P. A., Soon, D. K. W., Linnebjerg, H., Park, S., Chan, C., Yeo, A., Lim, M., Mace, K. F., & Wise, S. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278806 · Cited by 69
Chedid, V., Vijayvargiya, P., Carlson, P., Van Malderen, K., Acosta, A., Zinsmeister, A., & Camilleri, M. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13313 · Cited by 68
Self-citationBækdal, T. A., Borregaard, J., Hansen, C. W., Thomsen, M., & Anderson, T. W. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00756-2 · Cited by 67
Jones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13633 · Cited by 66
Vella, A., Bock, G., Giesler, P. D., Burton, D. B., Serra, D. B., Saylan, M. L., Deacon, C. F., Foley, J. E., Rizza, R. A., & Camilleri, M. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03235.x · Cited by 61
Self-citationAlbiglutide: A New GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
Trujillo, J. M., & Nuffer, W. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014545807 · Cited by 59
Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
Lu, W. J., Yang, Q., Sun, W., Woods, S. C., D'Alessio, D., & Tso, P. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00146.2007 · Cited by 55
Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men
Soon, D., Kothare, P. A., Linnebjerg, H., Park, S., Yuen, E., Mace, K. F., & Wise, S. D. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291622 · Cited by 54
Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids
Odunsi, S. T., Camilleri, M., Szarka, L. A., & ZINSMEISTER, A. R. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01283.x · Cited by 50
Self-citationThe role of the stomach in the control of appetite and the secretion of satiation peptides
Steinert, R. E., Meyer-Gerspach, A. C., & Beglinger, C. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00457.2011 · Cited by 50
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
Becker, R. H. A., Stechl, J., Steinstraesser, A., Golor, G., & Pellissier, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2647 · Cited by 49
Brønden, A., Albér, A., Rohde, U., Gasbjerg, L. S., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13080 · Cited by 46
The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study
Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M., Rayner, C. K., & Jones, K. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05198.x · Cited by 45
Selected Interventions in Nuclear Medicine: Gastrointestinal Motor Functions
Odunsi, S. T., & Camilleri, M. (2009) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.11.002 · Cited by 39
Self-citationExenatide effects on statin pharmacokinetics and lipid response
Kothare, P. A., Linnebjerg, H., Skrivanek, Z., Reddy, S., Mace, K., Pena, A., Han, J., Fineman, M., & Mitchell, M. (2007) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp45114 · Cited by 36
Nesfatin-1 stimulates cholecystokinin and suppresses peptide YY expression and secretion in mice
Ramesh, N., Mortazavi, S., & Unniappan, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.095 · Cited by 32
Effects of a Preload on Reduction of Food Intake by GLP-1 in Healthy Subjects
Degen, L. P., Oesch, S., Matzinger, D., Drewe, J., Knupp, M., Zimmerli, F., & Beglinger, C. (2006) · Digestion · doi:10.1159/000097585 · Cited by 29
Tibble, C. A., Cavaiola, T. S., & Henry, R. R. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.20 · Cited by 25
Linnebjerg, H., Kothare, P., Park, S., Mace, K., & Mitchell, M. (2009) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp47651 · Cited by 17
Gastric Emptying and the Personalized Management of Type 1 Diabetes
Marathe, C. S., Rayner, C. K., Wu, T., Jones, K. L., & Horowitz, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00849 · Cited by 8
Urva, S., Nauck, M. A., Coşkun, T., Cui, X., Haupt, A., Benson, C., & Loghin, C. (2019) · Diabetes · doi:10.2337/db19-58-or · Cited by 3
Cited by
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
“GLP-1 RAs have occasionally been described to exacerbate its symptoms, possibly because of the transient delay in gastric emptying subsequent to treatment initiation [78,79].”
BackgroundRisk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318
Silveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., Ho, A. M.-H., Nersessian, R. S. F., Lima, F. L. M., Silva, M. V., et al. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111091 · Cited by 259
Metadata
- Authors
- Maselli, D. B., & Camilleri, M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Camilleri, Michael
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer International Publishing
- Published
- 2020
- Volume
- 1307
- Pages
- 171-192
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W3008749018
- Cited by
- 248
- References
- 111
- Citations by year
- 2026: 44 · 2025: 74 · 2024: 68 · 2023: 31 · 2022: 17 · 2021: 9 · 2020: 5
- FWCI
- 70.74
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, gastric emptying, gastric motility, type 2 diabetes, obesity, exendin-4, GLP-1 analogues, proglucagon, insulin secretion, tachyphylaxis, GIP/GLP-1 receptor agonist, postprandial blood glucose, appetite
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Emptying, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.